Gilead Sciences Inc.
Moat Score — Gilead Sciences Inc.
Total Moat Score
18 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Gilead's deep patent portfolio and decades-long clinical and regulatory leadership in HIV treatment, anchored by Biktarvy and Descovy, create formidable barriers that few competitors can challenge. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | As an R&D-intensive branded pharmaceutical company, Gilead is not a low-cost producer — its advantage comes from patent-protected pricing rather than manufacturing cost efficiency. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | Patent exclusivity and the chronic, lifelong nature of HIV therapy support strong pricing power, though U.S. drug-pricing reform and payer rebate pressure are persistent constraints. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effect applies to pharmaceutical products — value comes from clinical efficacy and patent protection, not from other users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Patients on stable, effective chronic HIV therapy rarely switch regimens absent a clear reason, and physician prescribing habits plus payer formulary placement reinforce that inertia. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The HIV treatment market is effectively a duopoly between Gilead and ViiV Healthcare (GSK/Pfizer/Shionogi), a concentrated structure that limits new entrants, though Gilead's newer oncology and cell therapy areas are far more competitive. |